[Translation] A single-center, open-label, sequential administration clinical study to evaluate the drug-drug interactions between frutinib succinate capsules, itraconazole capsules, and rifampicin capsules in healthy adult subjects

主要研究目的：评价伊曲康唑胶囊、利福平胶囊分别对中国健康受试者口服丁二酸复瑞替尼胶囊后丁二酸复瑞替尼主要药代动力学参数的影响；次要研究目的：1）评价伊曲康唑胶囊、利福平胶囊分别对中国健康受试者口服丁二酸复瑞替尼胶囊后丁二酸复瑞替尼其他药代动力学参数的影响；2）评价中国健康受试者单剂量口服丁二酸复瑞替尼胶囊及分别与伊曲康唑胶囊、利福平胶囊联合用药的安全性；探索性目的：定性分析中国健康受试者单剂量口服丁二酸复瑞替尼胶囊及分别与伊曲康唑胶囊、利福平胶囊联合用药后粪便中的代谢物。

[Translation]

Main study objectives: To evaluate the effects of itraconazole capsules and rifampicin capsules on the main pharmacokinetic parameters of succinate succinate succinate succinate capsules in healthy Chinese subjects; Secondary study objectives: 1) To evaluate the effects of itraconazole capsules and rifampicin capsules on other pharmacokinetic parameters of succinate succinate succinate capsules in healthy Chinese subjects; 2) To evaluate the safety of single-dose oral administration of succinate succinate succinate capsules and combined administration with itraconazole capsules and rifampicin capsules in healthy Chinese subjects; Exploratory objectives: To qualitatively analyze the metabolites in feces of healthy Chinese subjects after single-dose oral administration of succinate succinate succinate capsules and combined administration with itraconazole capsules and rifampicin capsules.

Start Date09 Jun 2024

Sponsor / Collaborator

Fochon Pharmaceuticals Ltd.

[+1]

CTR20222655

/ CompletedPhase 1

[14C]SAF-189s在健康受试者体内的物质平衡临床试验

[Translation] Clinical trial of [14C]SAF-189s in healthy subjects: a study of the balance of substances in the body

主要研究目的： 1 定量分析男性健康受试者单次口服[14C]SAF-189s后，排泄物中的总放射性，获得人体放射性的累计排泄率和主要排泄途径； 2 考察男性健康受试者单次口服[14C]SAF-189s后，全血和血浆中的分配情况，血浆中总放射性的药代动力学，全血中总放射性的药代动力学（如适用）； 3 鉴定男性健康受试者单次口服[14C]SAF-189s后，血浆、尿液、粪便中的主要代谢产物，确定主要生物转化途径和主要代谢产物（接近或大于10%总放射性AUC）； 4 采用已验证的LC-MS/MS方法定量分析血浆中SAF-189s及其主要代谢产物（如适用）的浓度，获得血浆中SAF-189s及其主要代谢产物（如适用）的药代动力学参数。若项目需要，可采用已验证的LC-MS/MS方法定量分析尿液和/或粪便中SAF-189s及其主要代谢产物（如适用）的浓度，获得尿液和/或粪便中SAF-189s及其主要代谢产物（如适用）的药代动力学参数。次要研究目的：观察[14C]SAF-189s单次给药后男性健康受试者的安全性。

[Translation]

Main study objectives: 1 To quantitatively analyze the total radioactivity in excreta after a single oral administration of [14C]SAF-189s to healthy male subjects, and obtain the cumulative excretion rate and main excretion pathway of radioactivity in the human body; 2 To investigate the distribution of [14C]SAF-189s in whole blood and plasma, the pharmacokinetics of total radioactivity in plasma, and the pharmacokinetics of total radioactivity in whole blood (if applicable) after a single oral administration of [14C]SAF-189s to healthy male subjects; 3 To identify the main metabolites in plasma, urine, and feces after a single oral administration of [14C]SAF-189s to healthy male subjects, and determine the main biotransformation pathways and main metabolites (close to or greater than 10% of the total radioactivity AUC); 4 To quantitatively analyze the concentrations of SAF-189s and its main metabolites (if applicable) in plasma using a validated LC-MS/MS method, and obtain the pharmacokinetic parameters of SAF-189s and its main metabolites (if applicable) in plasma. If required by the project, the concentration of SAF-189s and its main metabolites (if applicable) in urine and/or feces can be quantitatively analyzed by a validated LC-MS/MS method to obtain the pharmacokinetic parameters of SAF-189s and its main metabolites (if applicable) in urine and/or feces. Secondary study objectives: To observe the safety of [14C]SAF-189s in healthy male subjects after a single dose.

Start Date10 Nov 2022

Sponsor / Collaborator

Fochon Pharmaceuticals Ltd.

[+1]

NCT06569420

/ Active, not recruitingPhase 3

A Randomized, Multicenter, Phase III Open-label Study: Efficacy and Safety of Comparing SAF-189s With Crizotinib in First-line Anaplastic Lymphoma Kinase-positive Advanced and Metastatic NSCLC

This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of SAF-189s versus crizotinib treatment in participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 1:1 into one of the two treatment groups to receive either SAF-189s (160 milligrams [mg] once daily [QD]) or crizotinib (250 mg BID) orally, respectively.

Start Date31 Dec 2021

Sponsor / Collaborator

Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

100 Clinical Results associated with Foritinib Succinate

100 Translational Medicine associated with Foritinib Succinate

100 Patents (Medical) associated with Foritinib Succinate

Literatures (Medical) associated with Foritinib Succinate

01 Sep 2024·The Lancet Respiratory Medicine

Foritinib, a type II ROS1 inhibitor for NSCLC

Article

Author: Ou, Sai-Hong Ignatius ; Lee, Jii Bum

01 Sep 2024·The Lancet Respiratory Medicine

Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study

Article

Author: Shi, Jianhua ; Cheng, Ying ; Jiang, Liyan ; Shen, Xionghu ; Liu, Yunpeng ; Wang, Changli ; Zhou, Jianying ; Zang, Aimin ; Fan, Yun ; Li, Wei ; Hu, Yanping ; Chen, Yuan ; Li, Mingjun ; Zhao, Qiong ; Chen, Gongyan ; Sun, Meili ; Dong, Xiaorong ; Cui, Jiuwei ; Wang, Baoqing ; Liu, Si-Yang Maggie ; Pan, Hongming ; Yi, Shanyong ; Luo, Pengfei ; Wu, Yi-Long ; Wang, Ke ; Liao, Wangjun ; Liu, Zhe ; Zhang, Zhiye ; Wang, Jun ; Ding, Cuimin ; Yang, Jin-Ji

BACKGROUNDCurrently approved targeted treatment for ROS1-rearranged non-small-cell lung cancer (NSCLC) has either inadequate intracranial activity or CNS-related toxicities. We evaluated the efficacy and safety of foritinib, a novel ALK and ROS1 inhibitor, in patients with advanced ROS1-rearranged NSCLC.METHODSThis two-part (phase 2a and 2b), multicentre, single-arm, open-label, phase 2 study was done in 29 centres in China. Eligible participants were adults (aged ≥18 years) with histologically or cytologically confirmed ROS1-rearranged, locally advanced or metastatic stage IIIB-IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 2 or less. Patients who had previously received no or one ROS1 inhibitor were enrolled into phase 2a, and patients who were naive to ROS1 inhibitor therapy were enrolled into phase 2b cohort 1. Participants in phase 2a received 80, 120, 160, or 210 mg foritinib succinate (foritinib) orally once daily over 21-day cycles; patients in phase 2b received the recommended phase 2 dose of 160 mg. The primary endpoint was objective response rate, assessed by the independent review committee in the full analysis set (ie, all participants who received at least one dose of study treatment). The safety analysis set included all participants who received at least one dose of study treatment and had available safety assessments. This study is ongoing and is registered with ClinicalTrials.gov, NCT04237805.FINDINGSBetween March 26, 2020, and Dec 29, 2022, 104 patients were enrolled and treated. Six patients who had previously received more than one ROS1 inhibitor were enrolled in phase 2a before a protocol amendment stating that patients in this phase should have received no more than one ROS1 inhibitor; these patients were included in the safety analysis but excluded from the efficacy analysis of the ROS1-inhibitor-pretreated cohort. Therefore, the efficacy analysis set (n=98) included 42 patients from phase 2a (17 who were ROS1 inhibitor naive and 25 who had previously received ROS1 inhibitor) and 56 patients from phase 2b cohort 1. In phase 2a, the objective response rate was 94% (95% CI 71-100; 16 of 17 patients) in patients who were ROS1 inhibitor naive and 40% (21-61; ten of 25) in patients who had previously received ROS1 inhibitor. In phase 2b cohort 1, the objective response rate was 88% (95% CI 76-95; 49 of 56 patients). In a prespecified exploratory analysis in 41 patients with CNS metastases at baseline, the objective response rate was 100% (95% CI 48-100; five of five patients) in patients in phase 2a who were ROS1 inhibitor naive, 40% (16-68; six of 15) in patients in phase 2a who had previously received ROS1 inhibitor, and 90% (70-99; 19 of 21) in patients in phase 2b cohort 1. Grade 3-4 treatment-related adverse events occurred in 33 (32%) of 104 patients; the most common were hyperglycaemia (12 [12%] patients) and electrocardiogram prolonged QT interval (six [6%]). Serious treatment-related adverse events occurred in 11 (11%) patients, with hyperglycaemia (six [6%]) being most common. No treatment-related adverse events led to death.INTERPRETATIONForitinib showed systemic and intracranial antitumour activity and good tolerability in ROS1-inhibitor-naive patients with ROS1-rearranged NSCLC. Foritinib represents a promising treatment for these patients, especially in those with CNS metastases.FUNDINGFosun Pharma, Wanbang Biopharmaceuticals, and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer.

01 Dec 2023·Drugs in R&D

Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults

Article

Author: Qin, Huiling ; Zhou, Yongchun ; Xiang, Xiao ; Hu, Wei ; Diao, Lei ; Wu, Zhuli ; Hui, Ai-Min ; Sun, Juan ; Tan, Yan ; Qiu, Jingjun

BACKGROUND AND OBJECTIVESThis study was conducted to investigate the effect of high-fat meals on the pharmacokinetics (PK) and safety profile of SAF-189s, a novel ALK/ROS1 inhibitor.METHODSThis was a single-center, phase I, open-label, crossover study in which healthy adults (≥18 years) were randomized (1:1) to two sequences of SAF-189s administration (fasted-fed or fed-fasted) separated by a 14-day washout. After a ≥10-h overnight fast, volunteers received SAF-189s 160 mg orally in a fasted state or 30 min after a high-fat, high-calorie meal. Similarity of pharmacokinetic parameters was concluded if the 90% CI for the geometric mean ratio (GMR) between the fed and fasted group fell within the predefined range of 0.80-1.25.RESULTSIn total, 24 subjects were enrolled and 23 completed the study. SAF-189s maximum plasma concentration (C_max; GMR: 109.1% [90% CI 103.1-115.4]) was comparable under fed (high-fat meal, n = 24) versus fasted (n = 23) conditions, with no effect on area under the plasma concentration-time curve from time 0 to t (AUC_0-t; GMR: 105.1% [90% CI 100.3-110.2]) and AUC from time 0 to infinity (AUC_0-∞; GMR: 105.5% [90% CI, 100.6-110.6]). In both groups, the median time to maximum plasma concentration (t_max) was around 6 h and mean plasma half-life (t_½) was around 35 h. Fed administration led to a lower incidence of treatment-emergent adverse events (TEAEs; 29.2% vs 54.2%), including gastrointestinal disorders (4.2% vs 41.7%) and headache (0.0% vs 12.5%), versus fasted administration.CONCLUSIONSA high-fat meal had minimal effect on the pharmacokinetic profile of SAF-189s compared with a fasted state following a single dose of 160 mg. Administration with a high-fat meal led to a lower incidence of TEAEs.

News (Medical) associated with Foritinib Succinate

30 Oct 2024

·www.prnewswire.com

Fosun Pharma Announces 2024Q3 Financial Results

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first three quarters of 2024. From January to September 2024, Fosun Pharma achieved revenue of RMB30.91 billion, an increase of about 5.74% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.84 billion, up by 24.58% YoY. In 2024, Fosun Pharma will further focus on innovative drugs and high-value devices, and continue to promote lean operations, cost reduction, efficiency improvement, and asset rationalization to optimize assets and financial structure, actively promote supply chain management and operational efficiency, and achieve healthy operating cash flow. In the first three quarters of 2024, the net cash flow from operating activities of Fosun Pharma was RMB2.99 billion, a year-on-year increase of 21.33%; the management expense ratio decreased by 0.15 percentage points YoY; excluding the impact of newly acquired companies, management expenses decreased by approximately RMB300 million on the same basis. Focusing on advantageous therapeutic areas with innovative R&D pipelines continue to advance In terms of innovative R&D, Fosun Pharma continues to focus on advantageous pipelines to achieve efficient results and continuous implementation of innovative products. In the first three quarters of 2024, Fosun Pharma's R&D expenditure totaled RMB3.92 billion. In particular, R&D expenses were RMB2.65 billion. In addition to independent R&D, the Group fully implemented an open R&D model, and incubated and invested in R&D projects by initiating/managing industrial funds and other diversified ways, so as to ensure the sustainability of innovation and R&D. Fosun Pharma's innovative drug business mainly covers the core therapeutic areas of solid tumors, hematological tumors and immuno-inflammatory diseases, with emphasis on the enhancement of the core technology platforms of antibody/ADCs, cellular therapy and small molecules, to create an open and global innovative R&D system, continuously enhance pipeline value, and promote the development and commercialization of its products. In the field of tumor immunotherapy, on September 13, 2024, Fosun Pharma announced it will acquire the 50% stake in Fosun Kite and will wholly own Fosun Kite (now renamed as "Fosun Kairos"). In the future, Fosun Kairos will serve as the core platform of Fosun Pharma's cell therapy, continue to focus on the field of tumor immunotherapy, as well as to promote the development and commercialization of existing licensed products, Axi-Cel (i.e. Fosun Kite's marketed product "Yi Kai Da") and Brexu-Cel (i.e. Fosun Kite's pipeline project FKC889), in Chinese mainland, Hong Kong SAR and Macau SAR with Kite Pharma. In the third quarter of 2024, Fosun Pharma's multiple independently developed innovative products and pipeline clinical trial results were announced in industry conferences and journals, further consolidating its dominant position in the fields of hematological tumors, breast cancer, lung cancer and other tumors. Particularly, the interim analysis results of the Phase III study of Foritinib Succinate (SAF-189s), an innovative drug independently developed to treat ALK-positiveb advanced non-small cell lung cancer (NSCLC), were released during the 2024 World Conference on Lung Cancer ("WCLC"). The above-mentioned studies have found that the overall efficacy of Foritinib Succinate is good. Compared with crizotinib treatment, it can significantly improve PFS and reduce the risk of CNS progression. Its safety is controllable, and no new safety signals appeared after treatment. Faritinib Succinate is expected to break through the current clinical difficulties faced in the treatment of ALK-positive NSCLC and bring new treatment options to NSCLC patients. The multicenter real-world study of Fosun Pharma's self-developed serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer was released at the 2024 WCLC. The ASTRUM-005R study provides additional empirical evidence to support the therapeutic value of serplulimab plus chemotherapy and complements the pivotal data from the ASTRUM-005 clinical trial. Additionally, during the reporting period, the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency (EMA) issued a positive opinion recommending approval for Fosun Pharma's self-developed serplulimab injection in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). The CHMP's opinion will be submitted to the European Commission (EC) as a reference for marketing authorization approval. Results of the phase 2 study of HLX22, an innovative anti-HER2 monoclonal antibody (mAb), in combination with Han Qu You (trastuzumab) and chemotherapy for the first-line treatment of HER2-positive advanced gastric/gastroesophageal junction (G/GEJ) cancer were presented on 2024 ESMO Gastrointestinal Cancers Congress (ESMO GI) and MED, a flagship clinical and translational research monthly journal by Cell Press. The results showed that add HLX22 to HLX02 (trastuzumab) and chemotherapy as first-line therapy improved efficacy in HER2-positive G/GEJ cancer patients with manageable safety. In September 2024, Fosun Pharma announced the Biologics License Application ("BLA") for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark: 达希斐®) for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients, was approved by the National Medical Products Administration ("NMPA"), becoming the first DaxibotulinumtoxinA-lanm approved for marketing in Chinese mainland. Additionally, the results of a Phase III multicenter, double-blind, placebo-controlled study conducted in China for the treatment of moderate to severe glabellar lines were published in the Journal of Plastic, Reconstructive & Aesthetic Surgery (JPRAS). The study demonstrates that the product provides durable efficacy and high safety in Chinese patients with moderate to severe glabellar lines. Actively implementing share repurchases and increasing holdings with continuous efforts on enhancing ESG Fosun Pharma, a company listed on both the A-share and H-share markets, and its controlling shareholder Fosun High Tech have actively engaged in share repurchases and increased holdings this year, demonstrating confidence in the Company's future development and further boosting market confidence. In the first three quarters of 2024, Fosun Pharma spent approximately RMB127 million and approximately HKD66.9 million to repurchase around 5.68 million A shares and 5.47 million H shares respectively. As of now, the H Share Repurchase Plan is still valid. In addition, the controlling shareholder Fosun High Tech, has spent a total of approximately RMB101 million to increase its holdings of around 4.30 million A shares of Fosun Pharma, under the latest Shareholding Increase Plan. Founded in 1994 and with three decades of development, Fosun Pharma has grown into a global innovation-driven pharmaceutical and healthcare industry group. The Company always regards innovation as its primary social responsibility, consistently focusing on unmet clinical needs, prioritizing innovative R&D, advancing the launch of innovative products, promoting drug accessibility and affordability, and driving high-quality corporate growth. Fosun Pharma maintained an A grade rating in MSCI ESG Ratings for three consecutive years and an A- rating in HSI ESG, ranking among the top tier in the healthcare industry for pharmaceuticals and biotechnology. It was also selected as a constituent of the Hang Seng (China A) Corporate Sustainability Benchmark Index ("HSCASUSB"), Hang Seng (China A) Corporate Sustainability Index ("HSCASUS"), and Hang Seng (Mainland and HK) Corporate Sustainability Index ("HSMHSUS"). With its sustained excellence in innovation and global operational capabilities, Fosun Pharma has been recognized by multiple authoritative institutions in innovative R&D, ESG and other areas. The Company ranked in the top four of China's 2023 Top 100 Pharmaceutical Industry, was included in the "China Best Managed Companies" List (BMC) for the second consecutive year and was listed in Forbes 2024 China ESG 50. In addition, the Company has actively introduced its independently developed artemisinin-based innovative products to Africa, providing a Chinese solution to the global fight against malaria. This initiative highlights the inclusive, diverse, and open nature of ESG and earned Fosun Pharma recognition as an "Inspirational ESG Case", serving as a model for corporate ESG practices. *** About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of "Innovation for Good Health", continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation. For more information, please visit the official website: SOURCE Fosun Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ImmunotherapyDrug ApprovalPhase 2Phase 3

100 Deals associated with Foritinib Succinate

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	NDA/BLA	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	06 Mar 2025
ALK positive Lung Cancer	Phase 3	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	31 Dec 2021
ALK-positive anaplastic large cell lymphoma	Phase 3	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	31 Dec 2021
Advanced cancer	Phase 2	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	14 Nov 2016
Advanced Malignant Solid Neoplasm	Phase 2	China	Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.	14 Nov 2016
Reactive oxygen species 1 positive non-small cell lung cancer	Phase 1	China	Shanghai Institute of Materia Medica Chinese Academy of Sci	09 Jun 2024
Reactive oxygen species 1 positive non-small cell lung cancer	Phase 1	China	Fochon Pharmaceuticals Ltd.	09 Jun 2024
Non-Small Cell Lung Cancer	IND Application	United States	Shanghai Institute of Materia Medica Chinese Academy of Sci	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


CTR20213144 (REMARK, WCLC2024) Manual	Phase 3	ALK positive Non-Small Cell Lung Cancer	275	SAF-189s	(rvlahxkfko) = cnzzymyevy nxmhwnpdxa (uigieliris ) View more	Positive	09 Sep 2024
CTR20213144 (REMARK, WCLC2024) Manual	Phase 3	ALK positive Non-Small Cell Lung Cancer	275	Crizotinib	(rvlahxkfko) = lhybimdocc nxmhwnpdxa (uigieliris ) View more	Positive	09 Sep 2024
NCT04237805 (not provided, Pubmed)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	104	Foritinib 80 mg	(rvjonjsjiy) = patolfijml clnxglcdiy (toxcpwacen, 71 - 100)	Positive	01 Jul 2024
NCT04237805 (not provided, Pubmed)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	104	Foritinib 120 mg	(rvjonjsjiy) = hxaxlbjlak clnxglcdiy (toxcpwacen, 21 - 61)	Positive	01 Jul 2024
NCT04237805 (ESMO_ASIA2022)	Phase 2	Reactive oxygen species 1 positive non-small cell lung cancer	-	SAF-189s	(cywcdspwem) = ejpubocpje bclenqsqve (bkoveibrcv ) View more	-	03 Dec 2022
NCT04237805 (ASCO2022) Manual	Phase 1/2	ALK positive Non-Small Cell Lung Cancer	195	SAF-189s	(nvevqlcmyu) = hyperglycemia (7%), hypertension (6%) and diarrhea (3%) cdumwxczzh (rnggdczaec ) View more	Positive	02 Jun 2022
NCT04237805 (ASCO2022) Manual	Phase 1/2	ALK positive Non-Small Cell Lung Cancer	195	SAF-189s (In phase 1 ALKi-naive)		Positive	02 Jun 2022
NCT04237805 (CSCO2020)	Phase 1/2	Neoplasm Metastasis \| ALK positive Non-Small Cell Lung Cancer	45	SAF-189s	(whgbxgoyir) = fqvjmzptss aiqdhzactp (yusljqndbo, 49.1 - 79.0) View more	-	19 Sep 2020
NCT04237805 (SAF-189s, Pubmed \| Acta Pharmacol Sin)	Phase 2	ROS1 fusion positive Neoplasms	-	SAF-189s	stxtivskqe(phirepjgdd) = lslwypbgpp gjxodsjdie (ashafcweix )	-	11 Sep 2020
NCT04237805 (ASCO2020)	Phase 1/2	Non-Small Cell Lung Cancer	36	SAF-189s	yaaxcvemkd(wtfipsrjwm) = 10 [27.8%] of 36 pts hsakymnypw (azsqseogbh ) View more	Positive	25 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Foritinib Succinate

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation